Lenalidomide
Found 8 free book(s)Multiple myeloma – lenalidomide Initial PBS authority ...
www.perthhaematology.com.au4203.1209 1 of 4 Multiple myeloma – lenalidomide Initial PBS authority application and supporting information Purpose of this form You must lodge this form for a patient starting initial Pharmaceutical Benefits Scheme (PBS) subsidised treatment with lenalidomide for
PATIENT INFORMATION NINLARO
www.ninlaro.comcapsules NINLARO is used with two other prescription medicines called REVLIMID® (lenalidomide) and dexamethasone. Read the Medication Guide that comes with REVLIMID® (lenalidomide). You can ask your healthcare provider or
MULTIPLE MYELOMA (MM) - Celgene
media.celgene.comArea of Research Phase 1 Phase 2 Phase 3 Post-Approval Research C C F P- esear C- C- T T appr LYMPHOMA REVLIMID® (lenalidomide) Mantle cell lymphoma: Relapsed/refractory . . . . . . . . . . Diffuse large B-cell lymphoma (ABC subtype): First-line .
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
media.celgene.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use REVLIMID® safely and effectively. See full prescribing information for
OUR CLINICAL TRIALS - Amgen Oncology
www.amgenoncology.comInformation as of 4/1/2016. Statements are based on the company’s current beliefs and Amgen disclaims any duty to update. For more information about Amgen and its business, including risks and uncertainties, please refer to Amgen’s filings with the SEC.
BC CANCER HAZARDOUS DRUG LIST
www.bccancer.bc.caBC CANCER HAZARDOUS DRUG LIST (Refer to: Pharmacy Directive VI-80 Hazardous Drug List) The BC Cancer Hazardous Drug List (BC Cancer HD List) is comprised of:
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.eu4 dexamethasone is delayed or discontinued, the administration of Empliciti should be based on clinical judgment (e.g. risk of hypersensitivity) (see section 4.4).
NCCN Clinical Practice Guidelines in Oncology (NCCN ...
www.nccn.orgVersion 4.2014, 08/22/14 © National Comprehensive Cancer Network, Inc. 2014, All rights reserved. The NCCN Guidelines and this illustration may not be reproduced in ...